Journal of clinical & experimental oncology最新文献_第2页

Prognostic Factors for Survival in Patients with Hepatocellular Carcinoma Treated By Transarterial Chemoembolization Using Drug-Eluting Beads 肝细胞癌经动脉化疗栓塞药物洗脱珠治疗的预后因素

Journal of clinical & experimental oncology Pub Date : 2018-10-15 DOI: 10.4172/2324-9110.1000230

N. Levasicc, Lesnik La, M. Garbajs, R. Dezman, P. Popovič

{"title":"Prognostic Factors for Survival in Patients with Hepatocellular Carcinoma Treated By Transarterial Chemoembolization Using Drug-Eluting Beads","authors":"N. Levasicc, Lesnik La, M. Garbajs, R. Dezman, P. Popovič","doi":"10.4172/2324-9110.1000230","DOIUrl":"https://doi.org/10.4172/2324-9110.1000230","url":null,"abstract":"Objective: Transarterial chemoembolization (TACE) is the most widely used therapeutic option in the treatment of intermediate hepatocellular carcinoma (HCC). Due to the heterogeneity of the intermediate stage patient population, survival rates are variable. The purpose of this retrospective study was to investigate prognostic factors in predicting overall survival in patients with HCC treated by transarterial chemoembolization using drug-eluting beads loaded with doxorubicin (DEBDOX TACE). \u0000Methods: 119 patients with intermediate stage HCC who had undergone DEBDOX TACE between February 2010 and January 2017 were studied. All procedures were performed under Cone Beam Computed Tomography (CBCT) control. Survival was calculated from the date of the first procedure. The survival rates and curves were calculated using the Kaplan-Meier method. Survival curves were compared using the log-rank test.Results: Overall, 362 procedures were performed (mean: 3.04 per patient). After a mean follow up of 24.5 ± 1.3 months, 83 patients had died and 36 survived. The average survival was 30.7 months ± 2.3 months (95% CI: 26.3-35.2 months). Median survival was 24.7 months. One-year, two-year and five-year survival rates were 84%, 47% and 3%, respectively. Independent survival prognostic factors were Child-Pugh class ,B (p=0.009), ascites (p=0.019), portal hypertension (p=0.024), bilirubin increase after procedure (p=0.002) and number of procedures (p=0.022).Conclusion: The presence of ascites, portal hypertension, Child-Pugh class B, Child-Pugh score, a higher increase in bilirubin levels after the procedure and a lower number of DEBDOX TACE procedures are significant prognostic factors in overall survival.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":"2018 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2018-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47118650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Changes of Circulating Endothelial Cells and Microparticles after Conventional Chemotherapy in Patients with Extensive Small-Cell Lung Cancer: Relevance to Prognosis and Treatment Response 癌症小细胞肺癌常规化疗后循环内皮细胞和微颗粒的变化与预后及治疗反应的相关性

Journal of clinical & experimental oncology Pub Date : 2018-10-15 DOI: 10.4172/2324-9110.1000228

F. Najjar, M. Alammar, G. Al-Massarani, Nissreen Almalla, A. Japawe, I. Banat, A. Ikhtiar

{"title":"Changes of Circulating Endothelial Cells and Microparticles after Conventional Chemotherapy in Patients with Extensive Small-Cell Lung Cancer: Relevance to Prognosis and Treatment Response","authors":"F. Najjar, M. Alammar, G. Al-Massarani, Nissreen Almalla, A. Japawe, I. Banat, A. Ikhtiar","doi":"10.4172/2324-9110.1000228","DOIUrl":"https://doi.org/10.4172/2324-9110.1000228","url":null,"abstract":"Objectives: Tumor angiogenesis is controlled by inhibitors and angiogenic factors. However, circulating endothelial cells (CECs) and microparticles (MPs) may be related to tumor angiogenesis in malignant tumors. We therefore investigated the significance of CECs and MPs variation for the prediction of treatment efficacy andprognosis in patients with extensive small-cell lung cancer (SCLC). Materials and methods: Isolation and quantification of CECs from the whole-blood was performed using immune magnetic separation (IMS) technique, while flow cytometry measurement (FCM) was used for enumerating MPs in plasma samples.Results: Twenty-six patients were included in this prospective study. The relative change in CEC and MP counts after treatment, correctly identified treatment response in 22/26 patients (84.6%) and 17/23 patients (73.9%) respectively. The difference in themedian duration of time to progression (TTP) between patient with high relative changes and those with low relative changes in CEC and MP values was not statistically significant (p=0.39 and p=0.2, respectively). By contrast, the increase in CEC and MP levels after chemotherapy tended to be inversely correlated with longer TTP duration (r²=0.111 and r²=0.171, respectively). However, onlym decreased MP values after chemotherapy have the trend to be correlated with longer TTP duration (r²=0.167).Conclusion: The relative change in CEC and MP values after treatment seems to be a useful biomarker for the evaluation of treatment response in patients with extensive SCLC. Moreover, this relative change in both biomarkers might be considered as a prognostic tool in SCLC.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":" ","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2018-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49501550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tibial Metastasis from Primary Carcinoma Tongue in a Young Male: A Case Report 年轻男性原发舌癌胫骨转移1例

Journal of clinical & experimental oncology Pub Date : 2018-10-15 DOI: 10.4172/2324-9110.1000226

M. SanjayKumar, M. Praveenkumar

引用次数: 0

Ways for Happy Living for Patients Diagnosed with Cancer 癌症患者快乐生活之道

Journal of clinical & experimental oncology Pub Date : 2018-10-15 DOI: 10.4172/2324-9110.1000231

F. Fortuna

引用次数: 0

New Psychotherapeutic Method in Psychosomatic Diseases like Cancer 癌症等身心疾病的新心理治疗方法

Journal of clinical & experimental oncology Pub Date : 2018-10-15 DOI: 10.4172/2324-9110.1000229

F. Fortuna

引用次数: 0

Circulating Levels of ADAM-10 and Soluble Standard CD44 in Patients with Hepatocellular Carcinoma: Relationship with Soluble TAM Receptors and their Ligands 肝细胞癌患者循环中ADAM-10和可溶性标准CD44水平:与可溶性TAM受体及其配体的关系

Journal of clinical & experimental oncology Pub Date : 2018-10-09 DOI: 10.4172/2324-9110.1000227

S. Uehara, Yuichi Fukuzawa, T. Matuyama, K. Gotoh

{"title":"Circulating Levels of ADAM-10 and Soluble Standard CD44 in Patients with Hepatocellular Carcinoma: Relationship with Soluble TAM Receptors and their Ligands","authors":"S. Uehara, Yuichi Fukuzawa, T. Matuyama, K. Gotoh","doi":"10.4172/2324-9110.1000227","DOIUrl":"https://doi.org/10.4172/2324-9110.1000227","url":null,"abstract":"Objective: The aim of the study was to examine correlations of the plasma levels of soluble (s) CD44 standard (std), and a disintegrin and metalloproteinase (ADAM) 10, with those of the soluble Tyro3, Axl, and Mer receptors (sTAMRs) and their ligands (GAS6 and PROS1) in patients with hepatocellular carcinoma (HCC), and other liver diseases.Method: The subjects were 55 patients with HCC, 4 with fulminant hepatitis (FH), 18 with acute hepatitis (AH), 10 with chronic hepatitis (CH), 20 with liver cirrhosis (LC), and 20 healthy normal controls (NCs). Plasma levels of sCD44std, ADAM10, sTAMRs, GAS6, PROS1, des-γ-carboxy prothrombin (DCP), and des-γ-carboxy GAS6 were measured by enzyme-linked immunosorbent assay.Results: The levels of sCD44std, ADAM10, sTAMRs, and Gas6 were significantly higher in HCC and other liver diseases (except CH) compared to those in NCs, but PROS1 levels in these diseases were significantly lower than those in NCs. These were significant positive correlations of sCD44std levels with ADAM10, and sMer levels in HCC and other liver diseases. SAxl was lower in stage HCC than in stage HCC, but GAS6 increased with progression of HCC stages. There was a significant positive correlation between the levels of DCP and des-γ-carboxy GAS6 in HCC. The subjects were roughly classified into three groups of HCC, inflammatory diseases, and normal controls using ratios of TAMRs and their ligands.Conclusion: The measurement of these blood factors facilitates a unified view of HCC therapy","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":"2018 1","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2018-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43525705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Intratumoral Therapy II: In Vitro and In Vivo Immunologic Testing and Therapy Options 肿瘤内治疗II:体外和体内免疫测试和治疗选择

Journal of clinical & experimental oncology Pub Date : 2018-08-16 DOI: 10.4172/2324-9110.1000222

Max H. Cohen, A. Ketcham, R. Herberman

{"title":"Intratumoral Therapy II: In Vitro and In Vivo Immunologic Testing and Therapy Options","authors":"Max H. Cohen, A. Ketcham, R. Herberman","doi":"10.4172/2324-9110.1000222","DOIUrl":"https://doi.org/10.4172/2324-9110.1000222","url":null,"abstract":"In a prospective randomized trial in patients with metastatic melanoma we compared two agents that had been used for metastatic melanoma intratumoral injections. Each patient had progressive metastatic disease no longer surgically controllable. Multiple metastases included satellitosis in the form of progressive nodules around the previously excised original melanoma site, and/or in-transit metastases in the form of observable tumor nodules progressing in a linear fashion toward a lymph node bearing area. As patients were receiving intratumoral injections, serially collected blood samples were tested for general immunologic reactivity and anti-melanoma reactivity. Specificity controls included breast cancer and lung cancer extracts. \u0000Additionally, as a measure of cell-mediated immunity, the patients were serially skin tested against antigens to measure general and melanoma-specific immunity. Depending on the patients’ clinical courses, we have divided the patients retrospectively into groups whose clinical courses were either better or worse than their cohorts, and determined the relationship between the immune testing and the clinical courses that the patients were experiencing as the serial testing was being conducted. Additionally, in a group of similar patients that were ‘cured for life’, we analyze their treatment in light of therapeutic attempts made by others to similarly haptenize melanoma antigens. We describe potential synergies between newly discovered melanoma therapies and intratumoral injection treatments and point out potential combination therapies that may offer the potential for enhancement of antitumor effects without increased systemic toxicity, a desirable goal now that combinations of recently acceptable immunotherapies have been associated with severe potential toxicities including death.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":"2018 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2018-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42598814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intratumoral Therapy I: Association of Immunotherapy with Permanent Long Term Cure of Metastatic Cancer 肿瘤内治疗I:免疫治疗与转移性癌症永久长期治愈的关系

Journal of clinical & experimental oncology Pub Date : 2018-08-16 DOI: 10.4172/2324-9110.1000221

Max H. Cohen, A. Ketcham, R. Herberman

{"title":"Intratumoral Therapy I: Association of Immunotherapy with Permanent Long Term Cure of Metastatic Cancer","authors":"Max H. Cohen, A. Ketcham, R. Herberman","doi":"10.4172/2324-9110.1000221","DOIUrl":"https://doi.org/10.4172/2324-9110.1000221","url":null,"abstract":"We have demonstrated in a randomized prospective study the superiority of intratumoral (intralesional) dinitrochlorobenzene (DNCB) compared to intratumoral (intralesional) bacillus Calmette-Guerin (BCG) in the treatment of progressive metastatic melanoma. The metastatic melanoma was in the form of satellitosis and/or in-transit metastases. We now demonstrate the ability of intralesional DNCB to permanently cure a selected group of patients with the same clinical criteria, and describe their clinical characteristics and treatment regimens. The described cured patients were followed for their remaining lifetimes, for up to 30 years, after being immunotherapeutically rendered free of metastatic cancer. They were each female, between the ages of 51 and 56 when intratumoral treatments were begun. Treatment was for progressive cutaneous and subcutaneous metastatic disease in the leg in two cases and for rapidly spreading scalp and forehead metastases in another. In each case the disease was not surgically controllable. Treatments were continued for 6 to 26 months. Subsequently the patients survived tumor free for either 18 years, dying at age 83; or for 24 years, dying at age 89; or for 30 years, dying at age 97. \u0000There has been a significant interest in recent years in immunotherapy for advanced cancer. The absence of systemic toxicity in the cured patients reported herein provides a basis for consideration of combining intratumoral treatments with current effective but systemically more toxic immunotherapeutic approaches to some metastatic cancers. Intratumoral treatments may be particularly applicable in cases of uncontrollable melanoma with cutaneous metastases, without evidence of distant spread, as in the current report.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":"2018 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2018-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44113570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early Detection of Cancer -The Good, the Bad, and the Ugly 早期发现癌症-好的，坏的和丑陋的

Journal of clinical & experimental oncology Pub Date : 2018-08-16 DOI: 10.4172/2324-9110.100E114

M. Retsky

引用次数: 0

Improving Pediatric Case Management in Home Health 改善家庭健康中的儿科病例管理

Journal of clinical & experimental oncology Pub Date : 2018-08-08 DOI: 10.4172/2324-9110.1000219

Nancy E Cisneros

引用次数: 0